EZS-8

EZS-8
Clinical data
Other names3-(2-Aminoethyl)quinazoline-2,4-dione
Drug classSerotonin 5-HT2A receptor partial agonist
ATC code
  • None
Identifiers
  • 3-(2-aminoethyl)-1H-quinazoline-2,4-dione
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC10H11N3O2
Molar mass205.217 g·mol−1
3D model (JSmol)
  • C1=CC=C2C(=C1)C(=O)N(C(=O)N2)CCN
  • InChI=1S/C10H11N3O2/c11-5-6-13-9(14)7-3-1-2-4-8(7)12-10(13)15/h1-4H,5-6,11H2,(H,12,15)
  • Key:NTAUXYQQSCPGHT-UHFFFAOYSA-N

EZS-8, also known as 3-(2-aminoethyl)quinazoline-2,4-dione, is a very-low-potency serotonin 5-HT2A receptor partial agonist related to ketanserin. It has about 0.15% of the potency (EC50Tooltip half-maximal effective concentration = 66,000 nM) and 46% of the efficacy (EmaxTooltip maximal efficacy) of serotonin as a serotonin 5-HT2A receptor agonist in vitro. The N-(2-methoxy)benzyl analogue of EZS-8, RH-34, has 250-fold greater potency as a serotonin 5-HT2A receptor agonist in comparison. EZS-8 was first described in the scientific literature by 1999. N-Benzyl derivatives of EZS-8 like RH-34 had been described as early as 1996 or 1998. Some other analogues of EZS-8 such as WL299 and WL163 have been described as well.

See also